Biohaven’s ion channel drug fails again, this time in major depressive disordernews2025-12-26T16:12:39+00:00December 26th, 2025|Endpoints News|
J&J axes eczema drug from $1.25B acquisitionnews2025-12-26T15:41:06+00:00December 26th, 2025|Endpoints News|
Neurocrine’s Ingrezza flunks pivotal study in dyskinetic cerebral palsynews2025-12-23T13:28:14+00:00December 23rd, 2025|Endpoints News|
Pfizer discloses patient death in Hympavzi hemophilia trialnews2025-12-23T12:00:08+00:00December 23rd, 2025|Endpoints News|
AstraZeneca bets up to $2B on Jacobio’s pan-KRAS inhibitor for cancernews2025-12-22T12:09:55+00:00December 22nd, 2025|Endpoints News|
Galapagos’ last asset posts mixed results as future remains in fluxnews2025-12-19T17:02:27+00:00December 19th, 2025|Endpoints News|
After year of triumph, Insmed stumbles with chronic rhinosinusitis fail, brings in new assetnews2025-12-18T16:35:36+00:00December 18th, 2025|Endpoints News|
Takeda’s $4B immunology drug achieves first Phase 3 successesnews2025-12-18T15:58:06+00:00December 18th, 2025|Endpoints News|
Moderna lands CEPI as new backer for its pandemic flu programnews2025-12-18T12:00:43+00:00December 18th, 2025|Endpoints News|
Lilly’s orforglipron is the first oral obesity therapy to show its worth in the maintenance settingnews2025-12-18T11:45:13+00:00December 18th, 2025|Endpoints News|
